GONGWIN BIOPHARM HOLDINGS CO., LTD. Gongwin Biopharm Holdings Co., Ltd. Stock
Equities
6617
KYG409471060
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 183 TWD | 0.00% |
|
-1.61% | -0.81% |
| Sales 2022 | 1.14M 35.1K | Sales 2023 | 18.92M 581K | Capitalization | 20.91B 642M |
|---|---|---|---|---|---|
| Net income 2022 | -254M -7.8M | Net income 2023 | -101M -3.1M | EV / Sales 2022 | 30,768 x |
| Net cash position 2022 | 964M 29.6M | Net cash position 2023 | 865M 26.57M | EV / Sales 2023 | 1,060 x |
| P/E ratio 2022 |
-140
x | P/E ratio 2023 |
-207
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 week | -1.61% | ||
| Current month | -4.69% | ||
| 1 month | -3.94% | ||
| 3 months | +6.09% | ||
| 6 months | +4.57% | ||
| Current year | -0.81% |
1 week
180.00
188.00
1 month
176.00200.00
Current year
167.00217.00
1 year
167.00320.00
3 years
150.00457.00
5 years
52.70457.00
10 years
47.50457.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mao Yuan Lin
CEO | Chief Executive Officer | - | 14-04-30 |
Wei Nan Hu
DFI | Director of Finance/CFO | - | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lieh Lin Chan
BRD | Director/Board Member | - | 18-12-03 |
Chih Tung Yang
BRD | Director/Board Member | - | 16-01-27 |
Lester John Wu
CHM | Chairman | - | 16-01-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 183 | 0.00% | 39,102 |
| 24-04-24 | 183 | +0.27% | 50,873 |
| 24-04-23 | 182.5 | +0.27% | 60,513 |
| 24-04-22 | 182 | -1.09% | 65,511 |
| 24-04-19 | 184 | -1.08% | 97,228 |
End-of-day quote Taipei Exchange, April 24, 2024
More quotes
Gongwin Biopharm Holdings Co Ltd is a company engaged in the research and development of anti-cancer medicine, especially focuses on the precise treatment to tumors. The Companyâs headquarter is located in Taiwan and it created a cross-regional platform composed of Taiwan, China Mainland and the United States. The new PTS drug researched and developed by the Company is a new drug product for cancer treatment combined with minimally invasive interventional therapy technology, including PTS100 for the treatment of liver cancer, PTS302 for the treatment of lung cancer, PTS-02 for the treatment of rare diseases, PTS500 for the treatment of malignant pleural effusion and pets medication GWA101 and others.
| 1st Jan change | Capi. | |
|---|---|---|
| -0.81% | 636M | |
| -2.82% | 103B | |
| +0.68% | 95.71B | |
| +1.37% | 22.02B | |
| -17.42% | 20.9B | |
| -9.28% | 17.85B | |
| -42.83% | 16.21B | |
| -15.67% | 15.52B | |
| +4.81% | 13.86B | |
| +32.45% | 12.04B |
- Stock Market
- Equities
- 6617 Stock
